Topicality: In recent years, ideas about the mechanisms of action of a local lysozyme containing antiseptic have been significantly expanded. Data on the availability of antiviral drugs and a positive effect on regeneration processes have been obtained. Objective: In order to further study the properties of the drug, its effect on the mechanisms of inflammation in a clinical setting and model of inflammation in an animal experiment was investigated. Material and methods: Clinical and immunological studies were conducted in 22 children aged 9-12 years, of which 10 people represented a group of healthy donors. 12 people with exacerbation of chronic catarrhal pharyngitis received the drug Lizak in the form of monotherapy according to the instructions. The oropharyngeal secretion was studied, where the pro-inflammatory cytokine interleukin-1β (Cytokine, RF), lactoferrin (Vector Best, RF), as well as the macrophage inflammatory protein MIP-1b (Hucaltbiotecknolgy, Netherlands) were determined by the ELISA method. As an analyzer, a Lab line reader (Austria) was used. The studies were carried out at two points: before the start of therapy and a day after its completion. Under the experimental conditions, a model of caraginan edema of rat paws was used, which, prior to the introduction of phlogogen, received per os drug lizak. The degree of edema was determined using a special installation with an installed micrometer for measuring the thickness of the feet in the time interval from 0 to 24 hours. In addition, the levels of proinflammatory cytokine interleukin-1β and anti-inflammatory interleukin-10 were determined in the blood serum of animals at the same time intervals. Statistics were carried out using the ‘t’ –Student criterion. Results: Under monotherapy with the drug Lysak in children with acute pharyngitis, a decrease in the content of proinflammatory factors, interleukin-1β and Mip-1b, in the oropharyngeal secretion is shown. When studying the effect of the drug on the development of aseptic inflammation (stage of exudation) in the foot of rats, it was found that the drug Lizak had an inhibitory effect on the development of edema in the range of 1-4 hours, after which its effect was not detected (24 hours). In the control group and the “pure” control group, inflammatory edema was detected compared to the initial level (p=0.02) at 4 hours and was not detected after 24 hours. The drug Lysac has the ability to inhibit the development of aseptic local inflammation in the initial stages of its development. Confirmation of the systemic nature of the action of the drug is to reduce the level of pro-inflammatory cytokine-interleukin-1 in the blood serum of animals by 4 hours from the onset of the inflammatory process. Conclusions: The drug Lizak actively reduces the levels of pro-inflammatory cytokines both systemically and with local use and has a pronounced decongestant effect.